Overview
Feng Ke practices practicing medicine in Shiyan, China.
Mr. Ke is highly rated in 1 condition, according to our data. His clinical expertise encompasses Retinoblastoma, Gliomatosis Cerebri, Dacryoadenitis, and Bone Tumor.
He is actively involved in clinical research, co-authoring 15 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Feng Ke
Is Feng Ke a top-rated expert for Retinoblastoma?
MediFind is an objective health platform that identifies experts based on real-world data. Feng Ke is classified as an Advanced expert for Retinoblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Feng Ke participate in research or clinical trials?
Yes. Feng Ke has published 15 articles and abstracts on conditions like Retinoblastoma. You can view a list of Feng Ke's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- RetinoblastomaMr. Ke isAdvanced. Learn about Retinoblastoma.
- Experienced
- Bone TumorMr. Ke isExperienced. Learn about Bone Tumor.
- DacryoadenitisMr. Ke isExperienced. Learn about Dacryoadenitis.
- Gliomatosis CerebriMr. Ke isExperienced. Learn about Gliomatosis Cerebri.